Deoxycorticosterone-d8
Based on 1 Customer Validation
Deoxycorticosterone-d8 is the deuterium labeled Deoxycorticosterone. Deoxycorticosterone is a steroid hormone produced by the adrenal gland that possesses mineralocorticoid activity and acts as an aldosterone precursor.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 97.77%
- CAS. Nr.: 55487-63-3
- Formel: C21H22D8O3
- Molecular Weight:338.51
-
Speicherung:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
In Vitro
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Anwendung
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS. Nr. 55487-63-3
-
Unlabeled CAS 64-85-7
-
Appearance Solid
-
Molecular Weight 338.51
-
Formel C21H22D8O3
-
Color White to off-white
-
SMILES
C[C@@]12[C@]([C@]3([C@@]([C@]4(C)C(C(C3)([2H])[2H])=C(C(=O)C(C4)([2H])[2H])[2H])(CC1)[H])[H])(CC[C@@]2(C(C(O)([2H])[2H])=O)[2H])[H]
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : ≥ 250 mg/mL (738.53 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Reinheit & Dokumentation
-
Data Sheet (276 KB)
-
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
[2]. KAGAWA CM, et al. Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt. Science. 1957 Nov 15;126(3281):1015-6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9541 mL | 14.7706 mL | 29.5412 mL | 73.8531 mL |
| 5 mM | 0.5908 mL | 2.9541 mL | 5.9082 mL | 14.7706 mL | |
| 10 mM | 0.2954 mL | 1.4771 mL | 2.9541 mL | 7.3853 mL | |
| 15 mM | 0.1969 mL | 0.9847 mL | 1.9694 mL | 4.9235 mL | |
| 20 mM | 0.1477 mL | 0.7385 mL | 1.4771 mL | 3.6927 mL | |
| 25 mM | 0.1182 mL | 0.5908 mL | 1.1816 mL | 2.9541 mL | |
| 30 mM | 0.0985 mL | 0.4924 mL | 0.9847 mL | 2.4618 mL | |
| 40 mM | 0.0739 mL | 0.3693 mL | 0.7385 mL | 1.8463 mL | |
| 50 mM | 0.0591 mL | 0.2954 mL | 0.5908 mL | 1.4771 mL | |
| 60 mM | 0.0492 mL | 0.2462 mL | 0.4924 mL | 1.2309 mL | |
| 80 mM | 0.0369 mL | 0.1846 mL | 0.3693 mL | 0.9232 mL | |
| 100 mM | 0.0295 mL | 0.1477 mL | 0.2954 mL | 0.7385 mL |
Deoxycorticosterone-d8 Related Classifications
HY-113414S Related Classifications
Powered by Bioz